Rhythm Biosciences Enrolls First Physician Participant in Colorectal Cancer Detection Test Program; Shares Jump 9%
MT Newswires Live
Feb 11
Rhythm Biosciences (ASX:RHY) enrolled the first physician participant in its ColoSTAT Access Program, a commercial deployment framework for its blood-based test for the detection of colorectal cancer, according to a Wednesday Australian bourse filing.
Under the program, participating clinicians receive an initial allocation of ColoSTAT tests at no cost and continued use of the test after the initial allocation is expected to be on a paid basis, the filing said. The program will be capped at 20 participants in Australia.
Rhythm Biosciences' shares jumped nearly 9% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.